PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

Abstract Background Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many patients receive sequential CRT (sCRT). The PACIFIC-5 trial aimed to eval...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yi-Long Wu, Lin Wu, Nan Bi, Timucin Cil, Hong Ge, Zhengfei Zhu, Chih-Liang Wang, Wei Zhang, Dongqing Lv, E. Mingyan, Jianguo Sun, Yi Pan, Maciej Krzakowski, Mustafa Dikilitas, Mehmet Ali Nahit Sendur, Young-Chul Kim, Yanjiao Yang, Rui Mao, Biao Zhang, Luhua Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-12-01
Col·lecció:	Journal of Hematology & Oncology
Matèries:	Non-small-cell lung cancer Immunotherapy Chemoradiotherapy Clinical trial Phase III Durvalumab
Accés en línia:	https://doi.org/10.1186/s13045-025-01768-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!